Onalespib

Generic Name: Onalespib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₃₁N_₃O_₃

CAS Number: 912999-49-6

Unique Ingredient Identifier: Q7Y33N57ZZ

Indication: Investigated for use/treatment in cancer/tumors (unspecified).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer

Phase 1

Completed

Conditions: Unresectable High Grade Fallopian Tube Serous Adenocarcinoma
Metastatic Primary Peritoneal Serous Adenocarcinoma
Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Recurrent Triple-Negative Breast Carcinoma
Refractory Primary Peritoneal Serous Adenocarcinoma
Unresectable Primary Peritoneal Serous Adenocarcinoma
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma
Metastatic Malignant Solid Neoplasm

Interventions: Drug: Olaparib
Drug: Onalespib

First Posted Date: 2016-09-13

Last Posted Date: 2023-04-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT02898207

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States

and more 5 locations

Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL

Phase 2

Terminated

Conditions: Refractory Anaplastic Large Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Recurrent Transformed Non-Hodgkin Lymphoma
Refractory Mantle Cell Lymphoma
Refractory Transformed Non-Hodgkin Lymphoma
Recurrent Anaplastic Large Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions: Drug: Onalespib

First Posted Date: 2015-10-09

Last Posted Date: 2022-09-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT02572453

Locations: 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 16 locations

Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Non-Small Cell Cancer AJCC v7

Interventions: Drug: Erlotinib Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Onalespib Lactate
Other: Pharmacological Study

First Posted Date: 2015-08-28

Last Posted Date: 2024-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 11

Registration Number: NCT02535338

Locations: 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 3 locations

Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Active, not recruiting

Conditions: Metastatic Malignant Solid Neoplasm
Advanced Malignant Solid Neoplasm
Unresectable Solid Neoplasm

Interventions: Drug: CDK Inhibitor AT7519
Other: Laboratory Biomarker Analysis
Drug: Onalespib
Other: Pharmacological Study

First Posted Date: 2015-07-21

Last Posted Date: 2024-11-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 29

Registration Number: NCT02503709

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

and more 3 locations

Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

Phase 1

Terminated

Conditions: Metastatic Breast Carcinoma
Stage IIIB Breast Cancer AJCC v7
Advanced Breast Carcinoma
Stage III Breast Cancer AJCC v7
Stage IV Breast Cancer AJCC v6 and v7
Triple-Negative Breast Carcinoma
Stage IIIA Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Onalespib
Drug: Paclitaxel
Other: Pharmacological Study

First Posted Date: 2015-06-17

Last Posted Date: 2022-11-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 31

Registration Number: NCT02474173

Locations: 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

and more 1 locations

Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin

Phase 1

Active, not recruiting

Conditions: Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7
Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7
Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7

Interventions: Drug: Cisplatin
Radiation: Intensity-Modulated Radiation Therapy
Other: Laboratory Biomarker Analysis
Drug: Onalespib
Other: Pharmacological Study

First Posted Date: 2015-03-06

Last Posted Date: 2024-10-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 2

Registration Number: NCT02381535

Locations: 🇨🇦
University Health Network-Princess Margaret Hospital, Toronto, Ontario, Canada
🇺🇸
Yale University, New Haven, Connecticut, United States

Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

Phase 1

Terminated

Conditions: Metastatic Malignant Solid Neoplasm
Stage III Cutaneous Melanoma AJCC v7
BRAF V600E Mutation Present
Stage IV Cutaneous Melanoma AJCC v6 and v7
BRAF V600K Mutation Present
Stage IIIB Cutaneous Melanoma AJCC v7
Unresectable Solid Neoplasm
Metastatic Melanoma
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7

Interventions: Drug: Dabrafenib
Other: Laboratory Biomarker Analysis
Drug: Onalespib
Other: Pharmacological Study
Drug: Trametinib

First Posted Date: 2014-03-27

Last Posted Date: 2024-10-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT02097225

Locations: 🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy